CC
ELEV

Caxton Corporation’s Elevation Oncology ELEV Stock Holding History

Caxton Corporation’s Portfolio ELEV Stock Details ELEV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-21,813
Closed -$14.5K – 14
2023
Q3 		$14.5K Buy
21,813
+88
+0.4% +$89 0.05% 9
2023
Q2 		$33K Sell
21,725
-46,599
-68% -$123K 0.1% 7
2023
Q1 		$130K Hold
68,324
– – 0.33% 12
2022
Q4 		$64.8K Buy
68,324
+27
+0% +$27 0.17% 14
2022
Q3 		$77K Buy
68,297
+4
+0% +$5 0.14% 13
2022
Q2 		$96K Buy
68,293
+14
+0% +$35 0.13% 12
2022
Q1 		$172K Buy
68,279
+12,980
+23% +$52K 0.21% 32
2021
Q4 		$333K Buy
55,299
+7,116
+15% +$49.1K 0.27% 41
2021
Q3 		$375K Buy
48,183
+8,597
+22% +$93K 0.3% 43
2021
Q2 		$537K Buy
+39,586
New +$489K 0.37% 40

Other funds holding ELEV

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
QUSVM
Qiming U.S. Ventures Management Bellevue, Washington $55.6M AUM 98.09% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Caxton Corporation's ELEV Position: Q4 2023 in Review

Caxton Corporation sold out of Elevation Oncology (ELEV) in Q4 2023, closing a stake of 21,813 shares — an estimated $14.5K sold.

Caxton Corporation first reported a position in ELEV in Q2 2021 and held it in 10 quarters. The position peaked at $537K in Q2 2021. 32 funds tracked by Wall St. Rank hold ELEV as of Q4 2023.

  • Caxton Corporation reported no remaining Elevation Oncology position as of Q4 2023 after selling out during the quarter.
  • Caxton Corporation sold 21,813 Elevation Oncology shares in Q4 2023, an estimated $14.5K.
  • Caxton Corporation first reported a position in Elevation Oncology in Q2 2021 and held it in 10 quarters.
  • Caxton Corporation's Elevation Oncology position peaked at $537K in Q2 2021.
  • 32 funds tracked by Wall St. Rank held Elevation Oncology as of Q4 2023.

Based on Caxton Corporation's 13F filing for Q4 2023, filed 14 Feb 2024.